{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:01:33Z","timestamp":1773417693384,"version":"3.50.1"},"reference-count":13,"publisher":"Japan Society for Clinical Immunology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2177\/jsci.40.90","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T22:15:06Z","timestamp":1497219306000},"page":"90-94","source":"Crossref","is-referenced-by-count":13,"title":["Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors"],"prefix":"10.2177","volume":"40","author":[{"given":"Shintaro","family":"IWAMA","sequence":"first","affiliation":[{"name":"Research Center of Health, Physical Fitness and Sports, Nagoya University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"ARIMA","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Larkin, J., et al.: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>N Engl J Med<\/i>. <b>373<\/b>: 23-34, 2015."},{"key":"2","unstructured":"2) Caturegli, P., et al.: Autoimmune hypophysitis. <i>Endocr Rev<\/i>. <b>26<\/b>: 599-614, 2005."},{"key":"3","unstructured":"3) Phan, G.Q., et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. <i>Proc Natl Acad Sci U S A<\/i>. <b>100<\/b>: 8372-8377, 2003."},{"key":"4","unstructured":"4) Iwama, S., et al.: Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. <i>Sci Transl Med<\/i>. <b>6<\/b>: 230ra245, 2014."},{"key":"5","unstructured":"5) Caturegli, P., et al.: Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. <i>Am J Pathol<\/i>. <b>186<\/b>: 3225-3235, 2016."},{"key":"6","unstructured":"6) Faje, A.: Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <i>Pituitary<\/i>. <b>19<\/b>: 82-92, 2016."},{"key":"7","unstructured":"7) Corsello, S.M., et al.: Endocrine side effects induced by immune checkpoint inhibitors. <i>J Clin Endocrinol Metab<\/i>. <b>98<\/b>: 1361-1375, 2013."},{"key":"8","unstructured":"8) Topalian, S.L., et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>N Engl J Med<\/i>. <b>366<\/b>: 2443-2454, 2012."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ishikawa, M., Oashi, K.: Case of hypophysitis caused by nivolumab. <i>J Dermatol<\/i>. 2016.","DOI":"10.1111\/1346-8138.13437"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Okano, Y., et al.: Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. <i>Endocr J<\/i>. 2016.","DOI":"10.1507\/endocrj.EJ16-0161"},{"key":"11","unstructured":"11) Gonzalez-Rodriguez, E., Rodriguez-Abreu, D., Spanish Group for Cancer I-B.: Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist<\/i>. <b>21<\/b>: 804-816, 2016."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Osorio, J.C., et al.: Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer. <i>Ann Oncol<\/i>. 2016. [Epub ahead of print]","DOI":"10.1093\/annonc\/mdw640"},{"key":"13","unstructured":"113) de Filette, J., et al.: Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. <i>J Clin Endocrinol Metab<\/i>. <b>101<\/b>: 4431-4439, 2016."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306b\u3088\u308b\u5185\u5206\u6ccc\u526f\u4f5c\u7528\u306e\u81e8\u5e8a\u3068\u305d\u306e\u30e1\u30ab\u30cb\u30ba\u30e0"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_90\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T22:17:46Z","timestamp":1569449866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_90\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.40.90","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}